Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

This study has been terminated.
Information provided by (Responsible Party):
Seattle Genetics, Inc. Identifier:
First received: August 23, 2012
Last updated: January 24, 2014
Last verified: January 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2013
  Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)